

RECEIVED
CENTRAL FAX CENTER

FEB 16 2006



GlaxoSmithKline

FAX

To 1626

Company USPTO

Fax 571-273-8300

From Allyson K. Jacobs

Tel 919-483-9105

Fax 919-483-7988

E-mail akj27836@gsk.com

Date 2/16/06

Pages including cover 6

Subject Serial No.: 10/530,810

Filing Date: 4/8/05


Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Attached:

Amendment Transmittal
Response to Restriction Requirement
Certificate of Transmission

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

FEB 16 2006

AMENDMENT TRANSMITTAL LETTER (Large Entity)					Docket No. PU4807USW	
Applicant(s): Brown et al.						
Application No. 10/530,810	Filing Date 4/8/05	Examiner Joseph R. Kosack	Customer No. 23347	Group Art Unit 1626	Confirmation No. 7741	
Invention: CHEMICAL COMPOUNDS						
COMMISSIONER FOR PATENTS:						
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	36 -	36 =	0	x \$50.00	\$0.00	
INDEP. CLAIMS	4 -	4 =	0	x \$200.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00	
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 07-1392 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
 Signature			Dated: 2/16/2006			
Kathryn L. Coulter, Reg. No. 45,889 Attorney for Applicants GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-1467 Facsimile: (919) 483-7988			<div>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____ (Date) _____ Signature of Person Mailing Correspondence _____ Typed or Printed Name of Person Mailing Correspondence</div>			
cc:						

P11LARGE/REV09

FEB 16 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Brown *et al.*

Application No.: 10/530,810

Confirmation No. 7741

Filed: April 8, 2005

Art Unit: 1626

Examiner: Joseph R. Kosack

For: CHEMICAL COMPOUNDS

Customer No.: 23347

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This paper is submitted in response to the Office Action mailed January 23, 2006. Early examination of the application on the merits is earnestly solicited.

Claims 1-14, 22-42 and 44 are pending in the present application. The Office Action states that the claims lack unity of invention, and requires the Applicants to make a selection of a group of claims for prosecution. According to the Office Action, Applicants must either select a group consisting of claims 1-8 as drawn to a single compound of the invention, or must select the group corresponding to claims 9-14, 22-42, and 44.

Applicants provisionally elect with traverse to prosecute claims 1-8 as drawn to the following compound:




which is exemplified in Example 178 on page 153 of the specification. Applicants expressly reserve the right to file divisional applications or take such other measures deemed necessary to protect the inventions in the remaining claims and compounds.

The Examiner is respectfully requested to reconsider the finding of lack of unity of invention, and to examine the genus of compounds of Formula (II) as defined in original claim 3 in the present application. According to the *Manual of Patent Examining Procedure (MPEP)*, a Markush grouping of alternatives for a chemical compound is considered to meet the requirements of unity of invention if all of the alternatives have a common property or activity and a common structure is present. *MPEP* § 1850. The *MPEP* states that a common structure is present when "a significant structural element is shared by all of the alternatives." *Id.* The compounds encompassed by Formula (II) as defined in claim 3 meet the requirements for unity of invention because the compounds encompassed by this claim share a common activity as inhibitors of protein tyrosine kinases and also share a significant structural element, an *N*,5-diphenyl-1,3-oxazol-2-amine core. Accordingly, it is requested that the Examiner examine this genus of compounds in the present application.

Should the Examiner have any further questions or comments regarding the prosecution of this case, it is respectfully requested that the Examiner telephone the undersigned agent so that further examination of this application may be expedited.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Kathryn L. Coulter
Attorney for Applicants
Registration No. 45,889

Date:

GlaxoSmithKline 2/16/2006
Five Moore Drive, PO Box 13398
Research Triangle Park, North Carolina 27709
Telephone: (919) 483-1467
Facsimile: (919) 483-7988

Doc Code:

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on 2/16/06
Date

Allyson K. Jacobs
Signature

Allyson K. Jacobs

Typed or printed name of person signing Certificate

Registration Number, if applicable

919-483-9105
Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.